Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,194 INR | -1.30% | +2.91% | +39.84% |
May. 30 | Transcript : Glenmark Pharmaceuticals Limited - Analyst/Investor Day | |
May. 29 | Assertio Therapeutics Names Brendan O'Grady as Chief Executive | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 47.11 and 25.26 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+39.84% | 4.04B | B- | ||
+19.64% | 43.3B | B- | ||
+21.25% | 22.22B | B+ | ||
+18.92% | 15.43B | - | ||
+53.19% | 12.72B | B | ||
-0.05% | 6.79B | - | - | |
-11.11% | 6.71B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.68% | 5.5B | B+ | ||
+6.91% | 4.78B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GLENMARK Stock
- Ratings Glenmark Pharmaceuticals Limited